Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 1, 2018

Primary Completion Date

June 30, 2019

Study Completion Date

December 31, 2019

Conditions
BK Virus Infection
Interventions
BIOLOGICAL

Viralym-B

"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.~Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."

Trial Locations (2)

77030

Texas Childrens Hospital, Houston

The Methodist Hospital system, Houston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AlloVir

INDUSTRY

NCT02313844 - Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B) | Biotech Hunter | Biotech Hunter